Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α_2A-adrenoreceptor agonist

References

• Abel S, Nichols DJ, Brearley CJ, et al. (2000). Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 49:64–71
   PubMed Web of Science ®Google Scholar
• Arnsten AF. (2010). The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother 10:1595–605
   PubMed Web of Science ®Google Scholar
• Bao X, Lu S, Liow JS, et al. (2012). [11C] Rhodamine-123: synthesis and biodistribution in rodents. Nucl Med Biol 39:1128–36
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity. Pediatrics 121:e73–84
   Google Scholar
• Bjaeldager PA, Jensen JB, Larsen NE, et al. (1980). Elimination of oral cimetidine in chronic renal failure and during haemodialysis. Br J Clin Pharmacol 9:585–92
   PubMedGoogle Scholar
• Boellner SW, Pennick M, Fiske K, et al. (2007). Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 27:1253–62
   PubMed Web of Science ®Google Scholar
• Burckhardt G. (2012). Drug transport by organic anion transporters (OATs). Pharmacol Ther 136:106–30
   PubMed Web of Science ®Google Scholar
• Carchman SH, Crowe Jr JT, Wright GJ. (1987). The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. J Clin Pharmacol 27:762–7
   Google Scholar
• Chen Y, Xu R, Yang J, et al. (2011). Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats. Life Sci 89:1–6
   Google Scholar
• Ciarimboli G, Deuster D, Knief A, et al. (2010). Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169–80
   PubMed Web of Science ®Google Scholar
• Cruz MP. (2010). Guanfacine extended-release tablets (intuniv), a nonstimulant selective alpha2a-adrenergic receptor agonist for attention-deficit/hyperactivity disorder. Pharm Ther 35:448–51
   Google Scholar
• Feng B, Obach RS, Burstein AH, et al. (2008). Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro–in vivo study. Clin Pharmacol Ther 83:567–76
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, et al. (1997). Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–81
   PubMed Web of Science ®Google Scholar
• He J, Qiu Z, Li N, et al. (2011). Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol 67:701–7
   Google Scholar
• He J, Yu Y, Prasad B, et al. (2014) Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction. Biopharm Drug Dispos 35:253–63
   PubMed Web of Science ®Google Scholar
• International Transporter Consortium, Giacomini KM, Huang SM, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• Katsuda H, Yamashita M, Katsura H, et al. (2010). Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33:1867–71
   PubMed Web of Science ®Google Scholar
• Kiechel JR. (1980). Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 10:25S–32S
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Katsura T, et al. (2009). Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem Pharmacol 77:1429–36
   PubMed Web of Science ®Google Scholar
• Kimura N, Okuda M, Inui K. (2005). Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 22:255–9
   PubMed Web of Science ®Google Scholar
• Kirch W, Köhler H, Braun W. (1980). Elimination of guanfacine in patients with normal and impaired renal function. Br J Clin Pharmacol 10:33S–5S
   Google Scholar
• Koepsell H. (2013). Polyspecific organic cation transporters and their biomedical relevance in kidney. Curr Opin Nephrol Hypertens 22:533–8
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227–51
   PubMed Web of Science ®Google Scholar
• Lal R, Sukbuntherng J, Luo W, et al. (2010). Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol 69:498–507
   PubMed Web of Science ®Google Scholar
• Larsson R, Bodemar G, Norlander B. (1979). Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol 15:153–7
   PubMedGoogle Scholar
• Larsson R, Erlanson P, Bodemar G, et al. (1982). The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol 13:163–70
   PubMedGoogle Scholar
• Li X, Li N, Sun X, et al. (2013). Development and validation of a simple, sensitive and accurate LC-MS/MS method for the determination of guanfacine, a selective α2A -adrenergicreceptor agonist, in plasma and its application to a pharmacokinetic study. Biomed Chromatogr 27:1708–13
   Google Scholar
• Lu Y, Nakanishi T, Fukazawa M, et al. (2014). How does whisky lower serum urate level? Phytother Res 28:788–90
   Google Scholar
• Morrissey KM, Stocker SL, Wittwer MB, et al. (2013). Renal transporters in drug development. Annu Rev Pharmacol Toxicol 53:503–29
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Haruta T, Shirasaka Y, et al. (2011). Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab Dispos 39:117–22
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, et al. (2011). Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 201:105–67
   PubMedGoogle Scholar
• Redolfi A, Borgogelli E, Lodola E. (1979) Blood level of cimetidine in relation to age. Eur J Clin Pharmacol 15:257–61
   PubMed Web of Science ®Google Scholar
• Safar ME, Loria Y, Weiss YA, et al. (1982). Antihypertensive effects and plasma levels of guanfacine in man. J Clin Pharmacol 22:385–90
   Google Scholar
• Shiga T, Hashiguchi M, Urae A, et al. (2000). Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther 67:222–8
   PubMed Web of Science ®Google Scholar
• Sogame Y, Kitamura A, Yabuki M, et al. (2013). Transport of biguanides by human organic cation transporter OCT2. Biomed Pharmacother 67:425–30
   Google Scholar
• Somogyi AA, Bochner F, Sallustio BC. (1992). Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther 51:379–87
   PubMed Web of Science ®Google Scholar
• Sorkin EM, Heel RC. (1986). Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 31:301–36
   Google Scholar
• Tahara H, Kusuhara H, Endou H, et al. (2005). A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337–45
   PubMed Web of Science ®Google Scholar
• Thévenod F, Ciarimboli G, Leistner M, et al. (2013). Substrate- and cell contact-dependent inhibitor affinity of human organic cation transporter 2: studies with two classical organic cation substrates and the novel substrate Cd2+. Mol Pharm 10:3045–56
   PubMed Web of Science ®Google Scholar
• Van Zwieten PA, Thoolen MJ, Timmermans PB. (1984). The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension 6:II28–33
   Google Scholar
• Wang ZJ, Yin OQ, TomLinson B, et al. (2008). OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 18:637–45
   PubMed Web of Science ®Google Scholar
• Zhao D, Gao Z, Han D, et al. (2012). Influence of rifampicin on the pharmacokinetics of salvianolic acid B may involve inhibition of organic anion transporting polypeptide (Oatp)-mediated influx. Phytother Res 26:118–21
   PubMed Web of Science ®Google Scholar